ICCC
ImmuCell Corporation
ICCC has the edge over NVO overall, supported by stronger fundamentals and lower modeled downside.
NVO
Novo Nordisk A/S
NVO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
ICCC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
ICCC's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ICCC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $4.26 | -58% |
| Current | 54x | $10.22 | — |
| Fair | 83x | $15.70 | +54% |
| Expensive | 809x | $154 | +1403% |
Historical ranges are pointers, not guarantees.
ICCC's PE is 54x, but its earnings don't support one, so it isn't a reliable read right now.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over ICCC in the historical PE scenario, which offers more potential upside but is not a forecast.
ICCC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect ICCC's earnings and revenue to decline, with profitability weakening.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over ICCC on the outlook, with more favorable earnings and revenue expectations.
ICCC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.19 | -34% |
| Q2 2026 | $0.07 | -68% |
| Q1 2026 | -$0.07 | -$0.03 |
| Q4 2025 | -$0.12 | +$0.14 |
| Q3 2025 | $0.29 | +$0.79 |
| Q2 2025 | $0.22 | +$0.75 |
| Q1 2025 | -$0.04 | +$0.47 |
| Q4 2024 | -$0.26 | +$0.49 |
ICCC's earnings per share have fallen from their peak: $0.19 over the past year, against $0.29 in late 2025.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ICCC on earnings, with more consistent year-over-year improvement.
ICCC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8M | +46% |
| Q2 2026 | $7.2M | +12% |
| Q1 2026 | $10.4M | +28% |
| Q4 2025 | $7.6M | -1.6% |
| Q3 2025 | $5.5M | -8.4% |
| Q2 2025 | $6.4M | +18% |
| Q1 2025 | $8.1M | +11% |
| Q4 2024 | $7.8M | +52% |
ICCC's revenue is growing: $8M last quarter, up 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 12% | +12 points |
| Q2 2026 | 27% | +18 points |
| Q1 2026 | 19% | +5.2 points |
| Q4 2025 | -0.8% | -8.8 points |
| Q3 2025 | 0.4% | +9.9 points |
| Q2 2025 | 8.8% | +34 points |
| Q1 2025 | 14% | +18 points |
| Q4 2024 | 8% | +28 points |
ICCC's operating margin was 12% last quarter, up 12 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over ICCC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ICCC on profitability, with a higher operating margin.
ICCC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$589.4K | +$1.2M |
| Q2 2026 | $2.3M | +58% |
| Q1 2026 | $3.4M | +173% |
| Q4 2025 | $310.2K | +$509.5K |
| Q3 2025 | -$1.8M | -$1M |
| Q2 2025 | $1.4M | +207% |
| Q1 2025 | $1.2M | +258% |
| Q4 2024 | -$199.3K | +$605.1K |
ICCC has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
ICCC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +108K shares |
| 1 year | +2.8% | +252K shares |
| 3 years | +20% | +1.6M shares |
| 5 years | +19% | +1.5M shares |
| Available history | +36% | +2.5M shares |
ICCC has 9M diluted shares, up 2.8% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ICCC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ICCC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Very low |
| Q2 2026 | -0.1x | Net Cash |
| Q1 2026 | 0.4x | Very low |
| Q4 2025 | 1.2x | Healthy |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 6.5x | High |
ICCC has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ICCC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 34.9 | Neutral |
ICCC's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ICCC PE vs Healthcare Sector
| Metric | ICCC | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 26x | 108% above |
| PE % | 36 | 29 | 7 pts above |
ICCC is trading at 54x earnings, a 108% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over ICCC on valuation relative to its sector.
ICCC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.1 | 1.2% above |
| 20 week MA | $10.3 | 0.8% below |
| 50 week MA | $8.54 | 20% above |
| 100 week MA | $7.15 | 43% above |
| 200 week MA | $6.02 | 70% above |
ICCC has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ICCC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.90 | $6.25 | +28% |
| 2021 | $6.25 | $8.31 | +33% |
| 2022 | $8.31 | $6.23 | -25% |
| 2023 | $6.23 | $5.09 | -18% |
| 2024 | $5.09 | $4.98 | -2.2% |
| 2025 | $4.98 | $6.12 | +23% |
| 2026 YTD | $6.12 | $10.2 | +67% |
ICCC has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.